Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Anacor Pharmaceutica (ANAC) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 4,500,140
  • Shares Outstanding, K 44,860
  • Annual Sales, $ 82,360 K
  • Annual Income, $ -61,250 K
  • 36-Month Beta 1.53
  • Price/Sales 54.64
  • Price/Book 99.79
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.46
  • Most Recent Earnings -0.36 on 05/10/16
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.00 +0.06%
on 06/09/16
100.47 -1.40%
on 05/26/16
-0.37 (-0.37%)
since 05/24/16
3-Month
52.00 +90.50%
on 04/01/16
101.08 -2.00%
on 05/16/16
+39.35 (+65.90%)
since 03/24/16
52-Week
52.00 +90.50%
on 04/01/16
156.93 -36.88%
on 07/21/15
+19.97 (+25.25%)
since 06/24/15

Most Recent Stories

More News
Drugmaker Pfizer decides not to break up business

TRENTON, N.J. (AP) — Drug giant Pfizer says it won't split into two publicly traded companies, despite pressure from investors frustrated by its lagging stock price, ending years of Wall Street speculation...

Pfizer on buying spree with AstraZeneca antibiotics deal

TRENTON, N.J. (AP) — Drugmaker Pfizer Inc. is continuing its shopping spree with its fourth acquisition since the April collapse of its planned $160 billion megadeal to buy rival Allergan PLC and move...

Hercules Announces Strong Second Quarter Financial Results with $0.32 NII per Share and a $0.31 Quarterly Dividend

--Q2 2016 Financial Highlights

Psoriasis Therapeutics Pipeline Review, H2 2015

Research and Markets (http://www.researchandmarkets.com/research/6tv9lw/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides...

Hypersensitivity Pipeline Review 2015

Research and Markets (http://www.researchandmarkets.com/research/42dhk8/hypersensitivity) has announced the addition of the "Hypersensitivity - Pipeline Review, H2 2015" report to their offering. This...

Leishmaniasis (Kala-Azar) - Pipeline Review 2015

Research and Markets (http://www.researchandmarkets.com/research/4vk3jg/leishmaniasis) has announced the addition of the "Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2015" report to their offering. This...

BUYINS.NET: EUFN, CLDT, FN, QLIK, ANAC, ELA Are Seasonally Ripe To Go Up In the Next Five Weeks

BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Ishares MSCI Europe Financials Sector Index Fund (NASDAQ:EUFN), Chatham Lodging Trust (NYSE:CLDT), First National Financial Services...

6 Drug Stocks That Look to Beat the Market in 2016

Don't miss these drug stocks that look to beat the market in 2016.

6 Drug Stocks That Look to Beat the Market in 2016

Don't miss these drug stocks that look to beat the market in 2016.

6 Drug Stocks That Look to Beat the Market in 2016

Don't miss these drug stocks that look to beat the market in 2016.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovery, development and commercialization of novel small-molecule therapeutics derived from its boron chemistry platform. Its three lead product candidates include two topically administered dermatologic compounds-AN2690, an antifungal...

See More

Support & Resistance

2nd Resistance Point 99.29
1st Resistance Point 99.25
Last Price 99.06
1st Support Level 99.18
2nd Support Level 99.15

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.